2 Tech Stocks In Small-Cap Space - BCT And BLG

  • February 11, 2019 08:30 PM AEDT
  • Team Kalkine
2 Tech Stocks In Small-Cap Space - BCT And BLG

The below-mentioned technology stocks have witnessed substantial growth in their share prices in the last few months. Let’s take a closer look at these stocks:

Bluechiip Limited (ASX: BCT)

Bluechiip Limited (ASX: BCT) is a technology company which is primarily involved in the development of IT-based temperature and identification tracking solutions. Recently, the company released an announcement regarding an Open Briefing interview with the company’s Managing Director Mr. Andrew McLellan. In the interview, Mr. Andrew has informed that Labcon has recently commenced marketing their Bluechiip-enabled Coldpoint range including on their website. He further informed that December 2018 was the first month of supply under the expanded agreement with Labcon and there is going to be a significant ramp-up in revenues over the next 3 to 6 months as the company delivers on the orders. He further told that the company is expecting to receive R&D tax refunds of around $1.0 Mn within the next two quarters for the 2017/18 financial year.

In the December quarter, the company reported sales revenue of $117,284 and sales receipts of $98,712. The Net operating cash outflow for the December 2018 quarter was $822,677, down from $1,123,242 for the September 2018 quarter. The reduction in the cash outflow was mainly due to reduced R&D expenses arising from near completion of some R&D activities and also fewer purchases for the quarter.

In the past six months, the share price of the company increased by 26.00 percent as on 7 February 2019. BCT’s shares traded at $0.068 (+7.937% intraday) with a market capitalization of circa $33.21 million as on 11 February 2019.

Bluglass Limited (ASX: BLG)

Bluglass Limited (ASX: BLG) is an Australian clean technology company which develops semiconductor technology called remote plasma chemical vapour deposition (RPCVD). Recently, the company has provided the latest RPCVD technical data, at the Photonics West Conference which is a leading event for photonics and laser industries.

AS per the release, the company’s Chief Technology Officer (CTO) Dr. Ian Mann highlighted about technical detail and competitive benefits of the Company’s patented RPCVD technology to manufacture GaN-based tunnel junctions in cascade LEDs. In December 2018, Bluglass Limited announced that it has successfully demonstrated functioning tunnel junctions, capitalizing on the unique low-temperature advantages of RPCVD.

Recently in January 2019, the company announced that it is going to collaborate with global semiconductor equipment leader, AIXTRON SE for the evaluation of BluGlass’ unique RPCVD technology and as per the company’s Managing Director Giles Bourne, this collaboration is an important step towards demonstrating the commercial viability of RPCVD in large scale manufacturing.

For the December quarter, the company reported net cash inflow from operating activities A$210k, Net cash used in investing activities of A$1,498k. As of 31 December 2018, the company had cash and cash equivalent of A$11,720k.

In the past three months, the share price of the company increased by 7.02% as on 8 February 2019. BLG’s shares traded at $0.305 with a market capitalization of circa $127.58 million as on 11 February 2019.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.



All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK